BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29251788)

  • 1. Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks.
    Quinet J; Jamard C; Burtin M; Lemasson M; Guerret S; Sureau C; Vaillant A; Cova L
    Hepatology; 2018 Jun; 67(6):2127-2140. PubMed ID: 29251788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection.
    Noordeen F; Scougall CA; Grosse A; Qiao Q; Ajilian BB; Reaiche-Miller G; Finnie J; Werner M; Broering R; Schlaak JF; Vaillant A; Jilbert AR
    PLoS One; 2015; 10(11):e0140909. PubMed ID: 26560490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
    Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
    Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
    Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
    Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.
    Foster WK; Miller DS; Scougall CA; Kotlarski I; Colonno RJ; Jilbert AR
    J Virol; 2005 May; 79(9):5819-32. PubMed ID: 15827196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
    Reaiche GY; Le Mire MF; Mason WS; Jilbert AR
    Virology; 2010 Oct; 406(2):286-92. PubMed ID: 20705309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients.
    Debing Y; Vanrusselt H; Degrauwe L; Silva de Oliveira DA; Kariuki CK; Ebwanga EJ; Bashir S; Merckx W; Thatikonda SK; Rajwanshi V; Gohil V; Hong J; Kum DB; Acosta Sanchez A; Chanda S; Blatt LM; Jekle A; Symons JA; Smith DB; Raboisson P; Lin TI; Beigelman L; Paeshuyse J
    Antiviral Res; 2024 Apr; 224():105835. PubMed ID: 38401714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.
    Foster WK; Miller DS; Marion PL; Colonno RJ; Kotlarski I; Jilbert AR
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2624-35. PubMed ID: 12878529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model.
    Le Guerhier F; Thermet A; Guerret S; Chevallier M; Jamard C; Gibbs CS; Trépo C; Cova L; Zoulim F
    J Hepatol; 2003 Mar; 38(3):328-34. PubMed ID: 12586299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.
    Thermet A; Buronfosse T; Werle-Lapostolle B; Chevallier M; Pradat P; Trepo C; Zoulim F; Cova L
    J Gen Virol; 2008 May; 89(Pt 5):1192-1201. PubMed ID: 18420797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo.
    Noordeen F; Vaillant A; Jilbert AR
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5299-306. PubMed ID: 23939904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibitory effect of trisodium phosphonoformate (PFA) on duck hepatitis B virus (DHBV) DNA in vivo].
    Chen X; Chen H
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):277-81. PubMed ID: 15617348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver.
    Reaiche-Miller GY; Thorpe M; Low HC; Qiao Q; Scougall CA; Mason WS; Litwin S; Jilbert AR
    Virology; 2013 Nov; 446(1-2):357-64. PubMed ID: 24074600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experimental study on the effect of combination therapy with lamivudine and famciclovir against duck hepatitis B virus in vivo].
    Chen Y; Guo S; Qi Z; Huang A
    Zhonghua Gan Zang Bing Za Zhi; 2001 Aug; 9(4):209-11. PubMed ID: 11602049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.
    Zoulim F; Berthillon P; Guerhier FL; Seigneres B; Germon S; Pichoud C; Cheng YC; Trepo C
    J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S460-3. PubMed ID: 12534778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
    Lim YS; Byun KS; Yoo BC; Kwon SY; Kim YJ; An J; Lee HC; Lee YS
    Gut; 2016 May; 65(5):852-60. PubMed ID: 25596179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral effects of PNA in duck hepatitis B virus infection model.
    Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
    Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
    Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
    Zoulim F; Białkowska-Warzecha J; Diculescu MM; Goldis AE; Heyne R; Mach T; Marcellin P; Petersen J; Simon K; Bendahmane S; Klauck I; Wasiak W; Janssen HL
    Hepatol Int; 2016 Sep; 10(5):779-88. PubMed ID: 27206517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.